Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

After paying almost $200 to get a shingles vaccine they later learned is publicly funded, a Tillsonburg, Ont., couple says ...

L-lysine is an essential amino acid. Another amino acid, arginine, counteracts the antiviral action of lysine. As a result, L ...

Shingrix, the CDC preferred vaccine for shingles, is on nationwide shortage due to high demand. The manufacturer, GlaxoSmithKline (GSK), cannot make enough vaccine to fill all orders. Because of this, ...